Sentence examples for pathogenic approach from inspiring English sources

This current pathogenic approach is not doing our mob any favours: hetero, homo or trans.

In this salutogenic study, the result differs from studies with a pathogenic approach.

With a salutogenic approach, factors influencing health are in focus in contrast to a pathogenic approach that focuses on the risk factors for disability.

Wild, Wiles and Allen (2013) make a useful distinction between work on successful ageing, which, while moving away from a pathogenic approach, is still focused on overcoming problems, and work on resilience, which focuses on the 'experience of vulnerability' and how this relates to older people feeling well despite having a chronic condition.

In some cases with a behavioural component…It's a dependency model… So, if you then say well we want a salutogenic, rather than a pathogenic, approach… For these kinds of whole person healing modalities where you're looking at all these co-morbidities improving, if it's being done properly, that one can begin to frame a cost assessment around that.

The aim of this work was to further investigate these correlations using both epidemiological and pathogenic approaches.

The knowledge of these new pathogenic approaches might identify novel therapeutic targets and therefore may improve the management of these patients.

Based upon the presumption that the AQP4-specific antibodies of NMO IgG are pathogenic, approaches that reduce humoral immunity, including plasmapheresis, intravenous IgG, and CD20 B-cell depletion, are commonly used in NMO therapy.

A pathogenic therapeutic approach cannot be prescribed if the cause of the nephropathy is unclear or even explicitly unknown, which is the case for 2 60% of RRT patients in various European countries [ 14].

When performed together with variant filtering on the basis of rare occurrence in populations, inheritance models, and the evidence of being pathogenic, this approach frequently can yield a singular diagnosis.

In this review, we go over major clinical trials conducted in SLE by analyzing any critical aspects related to study design, predefined endpoints and biological activity of novel compounds that may have hampered study outcome, despite the great effort of providing less toxic drugs within a targeted, pathogenic-based approach.